The Genomic Prostate Score® (GPS) test is a genomic assay that analyzes prostate cancer gene activity to provide more insights on prostate cancer aggressiveness. Having this information can help you, as the healthcare provider, determine next steps about recommending an active surveillance or treatment protocol. The Genomic Prostate Score® (GPS) test, often called the GPS test, uses tissue from a previous biopsy and looks for the activation of 17 genes associated with prostate cancer. It is designed for men with low, intermediate, and high-risk localized prostate cancer. Results of the test range from 0 to 100; the higher the number, the more aggressive the tumor.
Genomic Prostate Score® Benefits
The Genomic Prostate Score® Test has been studied in more than 10,000 patients and has been shown to provide:
- Critical, clinically meaningful endpoints
- Information about the risk of aggressive disease being found or developing
- Easy-to-understand test results that range from 0 to 100
- Insights into the likelihood of prostate cancer death and metastasis within 10 years
All of this information can put patients at ease and provide greater confidence in determining next steps.
Genomic Prostate Score® (GPS) Physician Video
Learn more about how the Genomic Prostate Score Test can help determine the potential aggressiveness of prostate cancer.
Below are additional frequently asked questions about the Genomic Prostate Score® (GPS)
Men who have a PSA < 20 ng/ml, have low or intermediate grade(Gleason 3+3=6 or 3+4=7) prostate cancer diagnosed via biopsy, and who have not received definitive therapy for their prostate cancer could benefit from the GPS test.
The Genomic Prostate Score test results determine if a patient may be a candidate for interventional therapy or if active surveillance could be appropriate. The test predicts prostate cancer specific metastasis (spread outside the prostate), mortality (death caused by prostate cancer) and risk of harboring adverse pathology. GPS results are provided as a Genomic Prostate Score (GPS) between 0 and 100. This score can provide information about the:
- Likelihood of freedom from high grade and/or non- organ-confined disease.
- Risk of prostate cancer death within 10 years (0-100%)
- Risk of prostate cancer metastasis within 10 years (0-100%)
- Risk of adverse pathology (>4+3 or pT3+) elsewhere in the prostate
See a sample GPS result report and learn more about interpreting these results.
The Genomic Prostate Score Test has been studied in more than 10,000 patients through numerous studies. A full list of publications can be found here.
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Feature
This real-world multi-institutional study found the Genomic Prostate Score Test is an effective, independent predictor of adverse pathology at surgery and provided patients with greater confidence and assurance in their decision.
Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy, Adverse Surgical Pathology in a Racially Diverse Population of Men
This study of 431 men found that the GPS test is a strong, independent measure of prostate cancer aggressiveness in both African American and Caucasian men as well as an effective test in predicting the recurrence of prostate cancer after a radical prostatectomy.
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality
This study validates the effectiveness of the Genomic Prostate Score® in predicting distant metastases (DM) and prostate cancer–specific mortality (PCSM) over 20 years.